Trends in molecular characteristics and antimicrobial resistance of group B streptococci: a multicenter study in Serbia, 2015-2020.

Anti-Bacterial Agents / pharmacology Clindamycin / pharmacology Drug Resistance, Bacterial / genetics Erythromycin / pharmacology Female Humans Infant, Newborn Infant, Newborn, Diseases / epidemiology Male Pregnancy Pregnancy Complications, Infectious / epidemiology Prevalence Serbia / epidemiology Streptococcal Infections / epidemiology Streptococcus agalactiae / drug effects Time Factors

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 01 2021
Historique:
received: 26 08 2020
accepted: 07 12 2020
entrez: 13 1 2021
pubmed: 14 1 2021
medline: 31 8 2021
Statut: epublish

Résumé

Group B Streptococcus (GBS) is a major cause of neonatal morbidity and mortality. Serbia has not fully implemented preventive measures against GBS neonatal diseases. Therefore, we aimed to assess the maternal GBS colonisation and invasive neonatal disease rate, to reveal the trends of antimicrobial resistance and serotype distribution of GBS from various patient groups. Randomly selected non-invasive (n = 991) and all invasive GBS (n = 80) collected throughout Serbia from 2015 to 2020 were tested for antimicrobial susceptibility, capsular typing, and hvgA detection. Overall, 877/5621 (15.6%) pregnant women were colonised with GBS. Invasive GBS infections incidence in infants (0.18/1000 live births) showed a decreasing trend (0.3 to 0.1/1000 live births). Type III was overrepresented in infants with invasive infections (n = 35, 58.3%), whereas type V predominated among colonised adults (n = 224, 25.5%) and those with noninvasive (n = 37, 32.5%) and invasive infections (n = 8, 40%). The hypervirulent clone III/ST17 was highly associated with invasive infections (n = 28, 35%), particularly late-onset disease (n = 9, 47.4%), showing an increase from 12.3 to 14.8%. The GBS resistance to erythromycin and clindamycin was 26.7% and 22.1%, respectively, with an upward trend. The emergence of the hypervirulent clone III/ST17 and the escalation in GBS resistance highlight an urgent need for continuous monitoring of GBS infections.

Identifiants

DOI: 10.1038/s41598-020-79354-3 PMID: 33436658 PMC: PMC7804007
pubmed: 33436658
doi: 10.1038/s41598-020-79354-3
pii: 10.1038/s41598-020-79354-3
pmc: PMC7804007
doi:

Substances chimiques

Anti-Bacterial Agents 0
Clindamycin 3U02EL437C
Erythromycin 63937KV33D

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

540

Références

Dutra, V. G. et al. Streptococcus agalactiae in Brazil: Serotype distribution, virulence determinants and antimicrobial susceptibility. BMC Infect. Dis. 14, 1–9 (2014).
doi: 10.1186/1471-2334-14-323
Brimil, N. et al. Epidemiology of Streptococcus agalactiae colonisation in Germany. Int. J. Med. Microbiol. 296, 39–44 (2006).
pubmed: 16361113 doi: 10.1016/j.ijmm.2005.11.001
Shabayek, S. & Spellerberg, B. Group B streptococcal colonisation, molecular characteristics, and epidemiology. Front. Microbiol. 9, 1–14 (2018).
doi: 10.3389/fmicb.2018.00437
Schrag, S. J. & Verani, J. R. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: Experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine 31, D20–D26 (2013).
pubmed: 23219695 doi: 10.1016/j.vaccine.2012.11.056
Schuchat, A. Epidemiology of group B streptococcal disease in the United States: Shifting paradigms. Clin. Microbiol. Rev. 11, 497–513 (1998).
pubmed: 9665980 pmcid: 88893 doi: 10.1128/CMR.11.3.497
Sendi, P., Johansson, L. & Norrby-Teglund, A. Invasive group B streptococcal disease in non-pregnant adults: A review with emphasis on skin and soft-tissue infections. Infection 36, 100–111 (2008).
pubmed: 18193384 doi: 10.1007/s15010-007-7251-0
Martins, E. R. et al. Streptococcus agalactiae causing neonatal infections in Portugal (2005–2015): Diversification and emergence of a CC17/PI-2b multidrug resistant sublineage. Front. Microbiol. 8, 1–9 (2017).
doi: 10.3389/fmicb.2017.00499
Poyart, C. et al. Invasive group B streptococcal infections in infants, France. Emerg. Infect. Dis. 14, 1647–1649 (2008).
pubmed: 18826837 pmcid: 2609873 doi: 10.3201/eid1410.080185
Kimura, K. et al. First molecular characterisation of group B streptococci with reduced penicillin susceptibility. Antimicrob. Agents Chemother. 52, 2890–2897 (2008).
pubmed: 18490507 pmcid: 2493108 doi: 10.1128/AAC.00185-08
Jamrozy, D. et al. Increasing incidence of group B streptococcus neonatal infections in the Netherlands is associated with clonal expansion of CC17 and CC23. Sci. Rep. 10, 9539 (2020).
pubmed: 32533007 pmcid: 7293262 doi: 10.1038/s41598-020-66214-3
Di Renzo, G. C. et al. Intrapartum GBS screening and antibiotic prophylaxis: A European consensus conference. J. Matern. Neonatal Med. 28, 766–782 (2015).
doi: 10.3109/14767058.2014.934804
Back, E. E., O’Grady, E. J. & Back, J. D. High rates of perinatal group B Streptococcus clindamycin and erythromycin resistance in an Upstate New York Hospital. Antimicrob. Agents Chemother. 56, 739–742 (2012).
pubmed: 22143529 pmcid: 3264262 doi: 10.1128/AAC.05794-11
Gygax, S. E. et al. Erythromycin and clindamycin resistance in group B streptococcal clinical isolates. Antimicrob. Agents Chemother. 50, 1875–1877 (2006).
pubmed: 16641466 pmcid: 1472207 doi: 10.1128/AAC.50.5.1875-1877.2006
Raabe, V. N. & Shane, A. L. Group B Streptococcus (Streptococcus agalactiae). Microbiol. Spectr. 7, GPP3-0007–2018 (2019).
doi: 10.1128/microbiolspec.GPP3-0007-2018
Liddy, H. & Holliman, R. Group B Streptococcus highly resistant to gentamicin. J. Antimicrob. Chemother. 50, 142–143 (2002).
pubmed: 12096024 doi: 10.1093/jac/dkf090
Hays, C. et al. Changing epidemiology of group B Streptococcus susceptibility to fluoroquinolones and aminoglycosides in France. Antimicrob. Agents Chemother. 60, 24–30 (2016).
doi: 10.1128/AAC.01374-16
Puopolo, K. M., Benitz, W. E. & Zaoutis, T. E. Committee on Fetus and Newborn; Committee on Infectious diseases. Management of neonates born at ≥35 0/7 weeks’ gestation with suspected or proven early-onset bacterial sepsis. Pediatrics 142, e20182894 (2018).
pubmed: 30455342 doi: 10.1542/peds.2018-2894
Ruppen, C., Lupo, A., Decosterd, L. & Sendi, P. Is Penicillin plus gentamicin synergistic against clinical group B Streptococcus isolates? An in vitro study. Front. Microbiol. 7, 1680 (2016).
pubmed: 27818657 pmcid: 5073528 doi: 10.3389/fmicb.2016.01680
Skjaervold, N. K., Bergh, K. & Bevanger, L. S. Distribution of PFGE types of invasive Norwegian group B streptococci in relation to serotypes. Indian J. Med. Res. Suppl. 119, 201–204 (2004).
Gajic, I. et al. Molecular epidemiology of invasive and non-invasive group B Streptococcus circulating in Serbia. Int. J. Med. Microbiol. 309, 19–25 (2019).
pubmed: 30389335 doi: 10.1016/j.ijmm.2018.10.005
Russell, N. J. et al. Maternal colonisation with Group B Streptococcus and serotype distribution worldwide: Systematic review and meta-analyses. Clin. Infect. Dis. 65, S100–S111 (2017).
pubmed: 29117327 pmcid: 5848259 doi: 10.1093/cid/cix658
Madrid, L. et al. Infant Group B streptococcal disease incidence and serotypes worldwide: Systematic review and meta-analyses. Clin. Infect. Dis. 65, S160–S172 (2017).
pubmed: 29117326 pmcid: 5850457 doi: 10.1093/cid/cix656
Vergadi, E. et al. Changes in the incidence and epidemiology of neonatal group B Streptococcal disease over the last two decades in Crete, Greece. Infect. Dis. Rep. 10, 56–59 (2018).
doi: 10.4081/idr.2018.7744
Johri, A. K. et al. Group B Streptococcus: Global incidence and vaccine development. Nat. Rev. Microbiol. 4, 932–942 (2006).
pubmed: 17088932 pmcid: 2742968 doi: 10.1038/nrmicro1552
Song, J. Y., Lim, J. H., Lim, S., Yong, Z. & Seo, H. S. Progress toward a group B streptococcal vaccine. Hum. Vaccines Immunother. 14, 2669–2681 (2018).
Joubrel, C. et al. Group B streptococcus neonatal invasive infections, France 2007–2012. Clin. Microbiol. Infect. 21, 910–916 (2015).
pubmed: 26055414 doi: 10.1016/j.cmi.2015.05.039
Creti, R. et al. Neonatal Group B Streptococcus infections: Prevention strategies, clinical and microbiologic characteristics in 7 years of surveillance. Pediatr. Infect. Dis. J. 36, 256–262 (2017).
pubmed: 27870810 doi: 10.1097/INF.0000000000001414
Manning, S. D. et al. Multilocus sequence types associated with neonatal group B streptococcal sepsis and meningitis in Canada. J. Clin. Microbiol. 47, 1143–1148 (2009).
pubmed: 19158264 pmcid: 2668308 doi: 10.1128/JCM.01424-08
Bellais, S. et al. Capsular switching in group B Streptococcus CC17 hypervirulent clone: A future challenge for polysaccharide vaccine development. J. Infect. Dis. 206, 1745–1752 (2012).
pubmed: 23002446 doi: 10.1093/infdis/jis605
Lu, B. et al. Molecular characteristics and antimicrobial resistance in invasive and non-invasive Group B Streptococcus between 2008 and 2015 in China. Diagn. Microbiol. Infect. Dis. 86, 351–357 (2016).
pubmed: 27692802 doi: 10.1016/j.diagmicrobio.2016.08.023
Medugu, N. et al. Group B streptococcal colonisation and transmission dynamics in pregnant women and their newborns in Nigeria: Implications for prevention strategies. Clin. Microbiol. Infect. 23, 673 (2017).
pubmed: 28274774 doi: 10.1016/j.cmi.2017.02.029
Teatero, S. et al. Clonal Complex 17 Group B Streptococcus strains causing invasive disease in neonates and adults originate from the same genetic pool. Sci. Rep. 6, 20047 (2016).
pubmed: 26843175 pmcid: 4740736 doi: 10.1038/srep20047
Björnsdóttir, E. S. et al. Changing epidemiology of group B streptococcal infections among adults in Iceland: 1975–2014. Clin. Microbiol. Infect. 22, 379 (2016).
pubmed: 26691681 doi: 10.1016/j.cmi.2015.11.020
Li, S. et al. Molecular characteristics of Streptococcus agalactiae in a mother–-baby prospective cohort study: Implication for vaccine development and insights into vertical transmission. Vaccine 36, 1941–1948 (2018).
pubmed: 29519594 doi: 10.1016/j.vaccine.2018.02.109
Pillai, P. et al. Streptococcus agalactiae pulsed-field gel electrophoresis patterns cross capsular types. Epidemiol. Infect. 137, 1420–1425 (2009).
pubmed: 19257912 doi: 10.1017/S0950268809002167
Brzychczy-Włoch, M. et al. Genetic characterisation and diversity of Streptococcus agalactiae isolates with macrolide resistance. J. Med. Microbiol. 59, 780–786 (2010).
pubmed: 20339021 doi: 10.1099/jmm.0.018176-0
Kardos, S. et al. High prevalence of group B streptococcus ST17 hypervirulent clone among non-pregnant patients from a Hungarian venereology clinic. BMC Infect. Dis. 19, 1–10 (2019).
doi: 10.1186/s12879-019-4626-7
Martins, E. R. et al. Analysis of Group B streptococcal isolates from infants and pregnant women in Portugal revealing two lineages with enhanced invasiveness. J. Clin. Microbiol. 45, 3224–3229 (2007).
pubmed: 17699641 pmcid: 2045366 doi: 10.1128/JCM.01182-07
CDC. Antibiotic Resistance Threats in the United States, 2019 (U.S. Department of Health and Human Services, Atlanta, 2019).
Yoon, I. A. et al. Clinical significance of serotype V among infants with invasive group B streptococcal infections in South Korea. Int. J. Infect. Dis. 38, 136–140 (2015).
pubmed: 26026823 doi: 10.1016/j.ijid.2015.05.017
Lamagni, T. L. et al. Emerging trends in the epidemiology of invasive group B streptococcal disease in England and Wales, 1991–2010. Clin. Infect. Dis. 57, 682–688 (2013).
pubmed: 23845950 doi: 10.1093/cid/cit337
Lopes, E. et al. Increasing macrolide resistance among Streptococcus agalactiae causing invasive disease in non-pregnant adults was driven by a single capsular-transformed lineage, Portugal, 2009 to 2015. Eurosurveillance 23, 1700473 (2018).
pmcid: 6152215 doi: 10.2807/1560-7917.ES.2018.23.21.1700473
Tsai, M. H. et al. Molecular characteristics and antimicrobial resistance of Group B streptococcus strains causing invasive disease in neonates and adults. Front. Microbiol. 10, 264 (2019).
pubmed: 30833941 pmcid: 6387999 doi: 10.3389/fmicb.2019.00264
Statistical Office of the Republic of Serbia. Statistical Pocketbook of the Republic of Serbia (accessed 06 May 2020); https://www.stat.gov.rs/en-US/oblasti/stanovnistvo/rodjeni-i-umrli/ (2020).
Lamy, M. C. et al. Rapid detection of the “highly virulent” group B streptococcus ST-17 clone. Microbes Infect. 8, 1714–1722 (2006).
pubmed: 16822689 doi: 10.1016/j.micinf.2006.02.008
Poyart, C. et al. Multiplex PCR assay for rapid and accurate capsular typing of group B streptococci. J. Clin. Microbiol. 45, 1985–1988 (2007).
pubmed: 17376884 pmcid: 1933079 doi: 10.1128/JCM.00159-07
Yao, K. et al. Capsular gene typing of Streptococcus agalactiae compared to serotyping by latex agglutination. J. Clin. Microbiol. 51, 503–507 (2013).
pubmed: 23196363 pmcid: 3553911 doi: 10.1128/JCM.02417-12
Kojic, M., Strahinic, I., Fira, D., Jovcic, B. & Topisirovic, L. Plasmid content and bacteriocin production by five strains of Lactococcus lactis isolated from semi-hard homemade cheese. Can. J. Microbiol. 52, 1110–1120 (2006).
pubmed: 17215903 doi: 10.1139/w06-072
Silva-Costa, C., Ramirez, M. & Melo-Cristino, J. Identification of macrolide-resistant clones of Streptococcus pyogenes in Portugal. Clin. Microbiol. Infect. 12, 513–518 (2006).
pubmed: 16700698 doi: 10.1111/j.1469-0691.2006.01408.x
The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 10.0 (accessed 10 January 2020); http://www.eucast.org/clinical_breakpoints/ (2020).
Société Française de Microbiologie. Recommandations 2020, V.1.1 Avril (accessed 01 may 2020); http://www.sfm-microbiologie.org/wp-content/uploads/2020/04/CASFM2020_Avril2020_V1.1.pdf/ (2020).
Compain, F. et al. Molecular characterisation of Streptococcus agalactiae isolates harboring small erm(T)-carrying plasmids. Antimicrob. Agents Chemother. 58, 6928–6930 (2014).
pubmed: 25136004 pmcid: 4249376 doi: 10.1128/AAC.03855-14
Grundmann, H., Hori, S. & Tanner, G. Determining confidence intervals when measuring genetic diversity and the discriminatory abilities of typing methods for microorganisms. J. Clin. Microbiol. 39, 4190–4192 (2001).
pubmed: 11682558 pmcid: 88515 doi: 10.1128/JCM.39.11.4190-4192.2001
Pinto, F. R., Melo-Cristino, J. & Ramirez, M. A confidence interval for the Wallace coefficient of concordance and its application to microbial typing methods. PLoS ONE 3, e3696 (2008).
pubmed: 19002246 pmcid: 2577298 doi: 10.1371/journal.pone.0003696

Auteurs

Dusan Kekic (D)

Institute for Microbiology and Immunology, Medical Faculty, University of Belgrade, Dr Subotica No. 1, 11000, Belgrade, Serbia. dusan_vk@yahoo.com.

Ina Gajic (I)

Institute for Microbiology and Immunology, Medical Faculty, University of Belgrade, Dr Subotica No. 1, 11000, Belgrade, Serbia.

Natasa Opavski (N)

Institute for Microbiology and Immunology, Medical Faculty, University of Belgrade, Dr Subotica No. 1, 11000, Belgrade, Serbia.

Milan Kojic (M)

Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11000, Belgrade, Serbia.

Goran Vukotic (G)

Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11000, Belgrade, Serbia.
Faculty of Biology, University of Belgrade, 11000, Belgrade, Serbia.

Aleksandra Smitran (A)

Institute for Microbiology and Immunology, Medical Faculty, University of Banja Luka, 78000, Banja Luka, Bosnia and Herzegovina.

Lidija Boskovic (L)

Department for Microbiology, University Hospital Center "Dr Dragisa Misovic", 11000, Belgrade, Serbia.

Marina Stojkovic (M)

Department for Microbiology, The Obstetrics and Gynaecology Clinic "Narodni Front", 11000, Belgrade, Serbia.

Lazar Ranin (L)

Institute for Microbiology and Immunology, Medical Faculty, University of Belgrade, Dr Subotica No. 1, 11000, Belgrade, Serbia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Trends in molecular characteristics and...
questionsmedicales.fr › Glucides › Hétérosides › Lincosamides › Lincomycine › Clindamycine › Trends in molecular characteristics and...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance microbienne aux médicaments › Résistance bactérienne aux médicaments › Trends in molecular characteristics and...
questionsmedicales.fr › Composés chimiques organiques › Lactones › Érythromycine › Trends in molecular characteristics and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Trends in molecular characteristics and...
questionsmedicales.fr › Personnes › Tranches d'âge › Nourrisson › Nouveau-né › Trends in molecular characteristics and...
questionsmedicales.fr › Malformations et maladies congénitales, héréditaires et néonatales › Maladies néonatales › Trends in molecular characteristics and...
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Reproduction › Grossesse › Trends in molecular characteristics and...
questionsmedicales.fr › Maladies urogénitales › Maladies de l'appareil urogénital féminin et complications de la grossesse › Complications de la grossesse › Complications infectieuses de la grossesse › Trends in molecular characteristics and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Prévalence › Trends in molecular characteristics and...
questionsmedicales.fr › Régions géographiques › Europe › Europe de l'Est › Serbie › Trends in molecular characteristics and...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à streptocoques › Trends in molecular characteristics and...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Lactobacillales › Streptococcaceae › Streptococcus › Streptococcus agalactiae › Trends in molecular characteristics and...
questionsmedicales.fr › Phénomènes physiques › Temps › Facteurs temps › Trends in molecular characteristics and...